Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 March 2020 | Story Leonie Bolleurs | Photo Leonie Bolleurs
Team from the UFS Microbiology department
From the Department of Microbiology and Biochemistry, were from the left, front: Dr Mariana Erasmus, Prof Martie Smit, Samantha McCarlie; back: Dr Carmien Tolmie; Samantha McCarlie, Prof Dirk Opperman, and Prof Robert Bragg. They believe publishing in high-impact factor journals reflects the quality of research delivered by the department.

Researchers in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS) published their work in four impact factor eleven journals in 2019/2020, and a fifth was accepted for publication in a journal with impact factor twelve in 2020. 

Two articles were published in Nature Communications, one in Drug Resistance Updates and one in Natural Product Reports. A fifth article is already available as an accepted article at Angewandte Chemie. Researchers in the department work on very diverse topics, as reflected in the titles of these articles: ‘A chemo-enzymatic oxidation cascade to activate C–H bonds with in situ generated H2O2’; ‘Native roles of Baeyer–Villiger monooxygenases in the microbial metabolism of natural compounds’; ‘The genome of a subterrestrial nematode reveals adaptations to heat’; ‘Molecular basis of bacterial disinfectant resistance’; and ‘CYP505E3 – a novel self‐sufficient ω‐7 in‐chain hydroxylase’.

Publishing in journals with a high impact factor is quite an achievement. Publishing in a journal with an impact factor of 3 is considered good and in most fields of study, publishing in journals with an impact factor of 10 or more is regarded as excellent. Impact factors are used to measure the importance of a journal by counting the number of times articles were cited in a certain time period. 

According to Prof Martie Smit, Head of the department, this is a reflection of the quality of research delivered by the department. “It is difficult and takes a lot of time and resources to publish in such high-impact journals.”

Contributing to their success in the department, is the work of their collaborators as well as the quality international postdoctoral researchers the department manages to attract with their emphasis on quality research.

Another highlight in the publication of these articles was that members of the department were corresponding authors of four of the five articles – meaning that the research was conducted in and driven from their laboratories, with UFS researchers taking primary responsibility for the preparation of the manuscripts and communicating with the editors of the journals.

Impacting society

Besides publishing in journals with high impact factors, these researchers are also making a difference to society. Prof Robert Bragg contributed to the study focusing on quality disinfectants. 

We are all aware of the danger of developing resistance to antibiotics. According to Prof Bragg, it is estimated that by 2050, 25 million people could be dying from antibiotic resistance-related bacterial infections per year. He says one of the best options to control diseases – not only bacterial diseases, but also viral diseases such as the Covid-19 outbreak – is good biosecurity and the use of good-quality disinfectants.

Researchers working on this study are trying to understand the development of resistance in bacteria to disinfectants. “This research group is currently investigating the ways in which bacteria become resistant to different high-quality disinfectants. The aim of this work is to discover new methods of resistance and then try to prevent bacteria from becoming resistant to commonly used disinfectants. One of the first aspects that needs investigation is to understand the methods of transfer of genetic information between bacteria. This work formed the basis of the review article written with master’s student Samantha McCarlie on transfer of genes that could code for disinfectant resistance in bacteria,” says Prof Bragg.

Studies about a nematode species discovered 1,3 km deep in a gold mine in Welkom and its ability to survive in extreme environments, made headlines about nine years ago. More extensive research has been performed on deep-space exploration of nematodes surviving extreme environments and were published in Nature Communications. Dr Mariana Erasmus, Assistant Director in the department and Technology Innovation Agency/UFS Saense Platform manager, says the study published in 2019 reveals these nematodes’ adaptation to heat and heat tolerance in an unusual ecosystem isolated from the surface biosphere. More studies on this can help humans learn how to adapt to a warming climate. 

TIA is an agency of the Department of Science and Innovation.

Three of the articles are from the Biocatalysis and Structural Biology group of Prof Dirk Opperman, Prof Martie Smit, and Dr Carmien Tolmie. Biocatalysis is a form of green chemistry that aims to produce chemicals in an environmentally friendly and sustainable manner. The research of the group focuses on using enzymes (proteins performing specialised chemical reactions) to insert an oxygen atom at a specific position in a starting material. Such reactions are difficult to perform using purely organic chemistry. 

The end products are value-added compounds of interest to, among others, the flavour and fragrance industry, which place a high premium on natural products. The work on the novel in‐chain hydroxylase was also patented internationally, because it can be used for the synthesis of a valuable flavour compound.
 
More to come

Besides the commitment of the team in Microbiology, it took multiple institutions, dedicated postdoctoral students, as well as time and money to publish this number of articles in high-impact journals in just over a year. With its 100-plus researchers varying from student researchers to NRF-rated scientists, everyone in the Department of Microbial, Biochemical and Food Biotechnology strives to produce high-quality research. 

And they promise, there is more to come. Watch this space …

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept